Med BioGene Engages the Howard Group Inc. to Provide Investor and Financial Relations Services

VANCOUVER, BRITISH COLUMBIA, Feb 15, 2007 (CCNMatthews via COMTEX News Network) --

Med BioGene Inc. (TSX VENTURE:MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has engaged The Howard Group Inc. (HG) of Calgary, Alberta, to provide investor and financial relations services to MBI.

Since 1988, HG has provided to public companies comprehensive investor and financial relations, business development, strategic planning and financing-related services. HG is also associated with the Insight Limited Partnership, a fund that invests in micro- and small-cap companies.

In addition to its ongoing investor relations services, HG will be providing ongoing commentary on MBI's activities in its free, online live newsletter, Insight. Interested parties are encouraged to subscribe to the newsletter feed by following this link: www.howardgroupinc.com/register.htm.

MBI has engaged HG for a term of twelve months, effective February 15, 2007. HG will receive a monthly fee of $6,000, plus approved reimbursement of expenditures. After six months from the effective date of the engagement, MBI may reduce the scope of HG's services, in which case HG's monthly fee will be $500, plus approved reimbursement of expenditures. Subject to the approval of MBI's board of directors, MBI will also grant to HG stock options to purchase 200,000 MBI common shares at an exercise price of $0.58 per share; a premium of 18% to the closing price of MBI's common shares on February 14, 2007 of $0.49. The stock options will have a term of 12 months from the date of grant; vest in four equal amounts every three months from the date of grant; be subject to a four month hold period; and be subject to acceptance for filing by the TSX Venture Exchange.

HG's investor relations services will be governed by Policy 3.4 "Investor Relations, Promotional and Market Making Activities" of the TSX Venture Exchange.

Erinn Broshko, Chief Executive Officer of MBI commented: "We have been very pleased with the progress made to date in our genetic biomarker programs to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease. The time is right to engage The Howard Group to build awareness in the financial and investment communities of Med BioGene's technology and successes."

About Med BioGene

MBI is a biotechnology company with advanced research and development in gene expression technology. MBI intends to utilize its expertise in gene expression to identifying those genes, known as "biomarkers," which mark the presence of various diseases. These biomarkers will be used as an effective tool for accurate and rapid screening and diagnosis and to unlock innovation in therapeutic development and treatment. With a robust set of qualified biomarkers, disease screening and diagnosis will be quicker, less invasive and more accurate and the safety of new therapeutics will be increased, drug products will get to patients in less time and treatment decisions will be more informed.

MBI is currently focused on developing and validating biomarkers in respect of lymphoma, leukemia, colorectal cancer and cardiovascular disease through its Gene Expression Profiling System(TM).

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements or information are only predictions based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. Our forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

For further information contact: